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Abstract
Smoking is one of the main risk factors that has affected human mortality and life
expectancy over the past century. Smoking accounts for a large part of the nonlin-
earities in the growth of life expectancy and of the geographic and sex differences in
mortality. As Bongaarts (2006) and Janssen (2018) suggested, accounting for smoking
could improve the quality of mortality forecasts due to the predictable nature of the
smoking epidemic. We propose a new Bayesian hierarchical model to forecast life ex-
pectancy at birth for both sexes and for 69 countries with good data on smoking-related
mortality. The main idea is to convert the forecast of the non-smoking life expectancy
at birth (i.e., life expectancy at birth removing the smoking effect) into life expectancy
forecast through the use of the age-specific smoking attributable fraction (ASSAF). We
introduce a new age-cohort model for the ASSAF and a Bayesian hierarchical model
for non-smoking life expectancy at birth. The forecast performance of the proposed
method is evaluated by out-of-sample validation compared with four other commonly
used methods for life expectancy forecasting. Improvements in forecast accuracy and
model calibration based on the new method are observed.
1 Introduction
Forecasting human mortality and life expectancy is of considerable importance for public
health policy, planning social security systems, life insurance, and other areas, particularly
as the world’s population continues to age. It is also a major component of population
projections, as it impacts the number of people alive and their distribution by age and sex.
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Population projection are themselves a major input to government planning at all levels,
as well as private sector planning, monitoring international development and environmental
goals, and research in the health and social sciences.
Many methods for forecasting mortality have been developed. The Lee-Carter method
(Lee and Carter, 1992) for forecasting age-specific mortality rates was a milestone and has
developed rapidly since it was proposed. Lee and Miller (2001) modified the Lee-Carter
method by matching estimated life expectancy with the observed value. Other variations
of the Lee-Carter method include adding a cohort effect (Renshaw and Haberman, 2006),
applying a functional data approach (Hyndman and Ullah, 2007; Shang, 2016), and incor-
porating biomedical information (Janssen et al., 2013). Bayesian Lee-Carter methods have
also been proposed (Pedroza, 2006; King and Soneji, 2011; Wi´sniowski et al., 2015). See
Booth et al. (2006) for a review.
The main organization that produces regularly updated mortality and population fore-
casts for all countries is the United Nations, which publishes these forecasts every two years
in the World Population Prospects (United Nations, 2017). Traditionally since the 1940s,
population projections have been done using deterministic methods that do not primarily
use statistical estimation methods or assess uncertainty in a statistical way (Whelpton, 1936;
Preston et al., 2000). In 2015, in a major advance, the UN changed the method for producing
their official mortality and population forecasts from the traditional deterministic method
to a Bayesian approach that estimates and assesses uncertainty about future trends in a
principled statistical way using Bayesian hierarchical models for life expectancy and fertility
(Raftery et al., 2012, 2013, 2014a; United Nations, 2015).
The basic approach of these methods is to extrapolate past trends in observed mortality
rates, which have been dominated by a monotone increasing trend in life expectancy for
over a century. However, it may also be helpful to include risk factors that can impact
health, and hence mortality (Janssen, 2018). This has been done, for example, for the
HIV/AIDS epidemic (Godwin and Raftery, 2017), alcohol consumption (Trias Llimo´s and
Janssen, 2019), and the obesity epidemic (Vidra et al., 2017). Another major factor is
smoking, which is mainly responsible for lung cancer and is a risk factor for many other
fatal diseases, and causes about 6 million deaths per year (Britton, 2017). Smoking can
account for some nonlinear trends, cohort effects, and between-country and between-sex
differentials observed in mortality, suggesting that it could be used to improve mortality and
life expectancy projections (Bongaarts, 2014).
Here we propose a Bayesian method for doing this for both sexes and multiple countries
jointly. It uses the smoking attributable fraction (SAF) of mortality, estimated by the
Peto-Lopez method (Peto et al., 1992; Bongaarts, 2006; Janssen et al., 2013; Stoeldraijer
et al., 2015). The proposed method consists of two main components, one to forecast the
age-specific SAF (ASSAF), and the other to forecast non-smoking life expectancy. Our
method develops male and female forecasts jointly, since the female smoking epidemic tends
to resemble the male one, but with a lag, and possibly a different maximum level, a fact
that can be used to improve forecasts. The female advantage in life expectancy is partly
due to smoking effects, and our method quantifies this and uses it to forecast the future life
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expectancy gap between females and males. We apply our method to 69 countries with high
quality data on the historical impact of smoking on mortality.
The paper is organized as follows. The methodology is described in Section 2. Section
2.3 describes the method for estimating and forecasting the ASSAF. Section 2.4 presents the
estimation and forecasting method for non-smoking life expectancy. Section 2.5 describes
our model for the gap between male and female life expectancy to complete the coherent
projection. An out-of-sample validation experiment is reported in Section 3 to evaluate
and compare the projection accuracy and calibration of our model with several benchmark
methods. We then study the details of the forecast results for four selected countries in
Section 4. We conclude with a discussion in Section 5.
2 Method
2.1 Notation
We use indices ` for country (always as a superscript unless otherwise indicated), s for sex,
t for time (usually in terms of the year), and c for cohort (usually in terms of the year of
birth). We use x to denote the left end of an age group, i.e., x represents the a-year age
group [x, x+ a), and x+ represents the age group [x,+∞).
A key general concept in our approach is the smoking attributable fraction (SAF) of
mortality for a population of interest. This is defined as the proportion by which mortality
would be reduced if the population were not exposed to smoking. We focus on the age-specific
SAF (ASSAF) of mortality for age group x in country ` and time period t, denoted by y`x,t.
The all-age smoking attributable fraction (ASAF) of mortality is defined as a weighted
average of the ASSAF over all age groups, where the weights are the age-specific mortality
rates. We use the symbols d, e0, and e
NS
0 to denote the mortality rate, the life expectancy
at birth, and the non-smoking life expectancy at birth, respectively.
We denote by N[u,v](λ, κ) the truncated normal distribution with mean λ and variance
κ on the support [u, v] (the subscript [u, v] is omitted if supported on the whole real line),
by G(λ, κ) the Gamma distribution with mean λ/κ and shape parameter κ, by IG(λ, κ) the
inverse-Gamma distribution with mean κ/(λ− 1) and shape parameter κ, and by U[u,v] the
continuous uniform distribution on the support [u, v]. We denote the cardinality of a set
A by |A| and the absolute value of a number b by |b|. A truncated function is written as
b+ := max{b, 0}.
2.2 Data
To calculate the ASAF and ASSAF, we need annual death counts by country, age group,
sex, and cause of death from the WHO Mortality Database (World Health Organization,
2017), which covers data from 1950 to 2015 for more than 130 countries and regions around
the world. This dataset comprises death counts registered in national vital registration
systems and is coded under the rules of the International Classification of Diseases (ICD).
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Quinquennial population, mortality rates, and life expectancy at birth were obtained from
the 2017 Revision of the World Population Prospects (United Nations, 2017) for each country,
sex, and age group.
2.3 Age-specific Smoking Attributable Fraction
We use estimates of the smoking attributable fraction (SAF) obtained with the Peto-Lopez
method, an indirect method based on the observed lung cancer count data (Peto et al., 1992;
Kong et al., 2016; Li and Raftery, 2019). Here we use a modified version of the Peto-Lopez
method proposed by Rostron and Wilmoth (2011) to estimate the ASSAF. The modified
method calculates the ASSAF for all 5-year age groups from 35 to 100, which is finer than
the original Peto-Lopez method. Also, the reference lung cancer mortality rates used in the
original Peto-Lopez method were underestimated because of selection bias, and the modified
method addresses this by introducing an inflation factor. Because of data quality issues, we
set ASSAF for age groups less than 40 to 0, and ASSAF for age groups 85 and older to the
same value as that for the 80–84 age group. These rules follow the guidelines in Peto et al.
(1992) and Rostron and Wilmoth (2011) with minor modifications, and result in nine age
groups with non-zero ASSAF. The left panel of Figure 1 shows the estimated quinquennial
ASSAF of US males for all nine age groups (shown in different colors) from 1953 to 2013.
2.3.1 Estimation and Forecasting: Age-cohort Modeling
We propose a probabilistic age-cohort approach to estimate and forecast the ASSAF for the
male population. The age-cohort plot of the US male ASSAF (right panel) in Figure 1 has
two main features that lead to our modeling. First, the ASSAF can be well approximated
by the product of an age effect and a cohort effect. The ASSAF of age group 80+ tends to
shift horizontally from other age groups for most of the countries (e.g., see the red dashed
line in the age-cohort plot of Figure 1 for the case of US males). Hence, we apply a cohort
effect τ for all age groups less than 80, and a separate cohort effect τ˜ for the 80+ age group.
The probabilistic model of ASSAF in country ` is
y`x,t
ind∼ N (ξ`xτ `t−x1x 6=80 + ξ`xτ˜ `t−x1x=80, σ2` ), (1)
where x takes values in {40, 45, 50, 55, 60, 65, 70, 75, 80}. To ensure identifiability, we set
ξ`40 = 1 for all countries. Eq. (1) is also closely related to a low-rank matrix completion
method. The age-cohort matrix based on the observed period ASSAF inevitably contains
missing values since we do not observe the ASSAF of early cohorts at young ages or that of
late cohorts at old ages (see Figure 2).
Second, the cohort pattern of the male ASSAF has a strong increasing-peaking-declining
pattern. This trend can be well captured by a five-parameter double logistic function (Meyer,
1994):
g(c|θ) := k
1 + exp{−41(c− 1873−42)} −
k
1 + exp{−43(c− 1873−42 −44)} , (2)
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Figure 1: Age-specific smoking attributable fractions (ASSAF) for the male population in
the United States from 1950-2015. Left: Age-period plot. The horizontal axis is the year
of observation and colors differentiate age groups. Right: Age-cohort plot. The horizontal
axis is the year of birth for all cohorts, where the values for each age group are shown by a
different color.
Figure 2: Transformation from age-period matrix (left) to age-cohort matrix (right). Black
and grey cells represent observed and missing values, respectively.
where θ := (41,42,43,44, k). The double logistic curve is a flexible parametric curve,
which has been used in many scientific fields such as hematology, phenology, and agricultural
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science. Due to its scientific interpretability, it is often used to describe social change, diffu-
sion, and substitution processes (Gru¨bler et al., 1999; Fokas, 2007; Kucharavy and De Guio,
2011). Examples of the use of a double logistic curve to describe dynamics in human de-
mography include mortality rates (Marchetti et al., 1996), life expectancy at birth (Raftery
et al., 2013), and total fertility rates (Alkema et al., 2011).
Most developed countries have already entered the declining stage of the smoking epi-
demic. The epidemic started in the early 1900s with a steady increase until the 1950s-
60s when the adverse impact of smoking became widely known and anti-smoking measures
started to be put in place. Since then, the smoking epidemic has continued to decline. Thus
the cohort effect of smoking exhibits a similar increasing-peaking-decreasing trend, which
can be captured naturally by the double logistic curve.
The cohort effect τ˜ for ages 80+ is just a horizontal shift of the cohort effect τ for younger
ages, so we use two related double logistic curves to bridge them:
τ `c |θ`, σ2[τ ] ind∼ N (g(c|θ`), σ2[τ ]), τ˜ `c |θ˜`, σ2[τ ] ind∼ N (g(c|θ˜`), σ2[τ ]), (3)
where c := t − x, θ` := (4`1,4`2,4`3,4`4, k`), and θ˜` := (4`1,4`2,4`3,4`4 + δ`, k`). Here δ` is
a shift parameter controlling the amount of horizontal translation τ˜ can make with respect
to τ .
We use a three-level Bayesian hierarchical model (BHM) to estimate and forecast male
ASSAF for all countries of interest jointly. Level 1 models the observed male ASSAF in
terms of the tensor product of the age effect and the cohort effect (i.e., Eq. (1)). Level
2 models the distributions (conditioning on the global parameters) of the country-specific
age effect ξ`x, the country-specific cohort effects τ
`
c and τ˜
`
c in Eq. (3), the country-specific
parameters θ` and θ˜` of the double logistic function, and the country-specific measurement
variance σ2` . Level 3 sets hyperpriors on the global parameters
ψ := ({µ[β]x }x 6=40, {σ2[β]x }x 6=40, σ2, σ2[τ ], µ41 , µ42 , σ242 , µ43 , µ44 , σ244 , µk, σ2k, µδ, σ2δ ).
More details of the specification of the full model are given in the Appendix A.
The left and right panels of Figure 3 plot the cohort effects and age effect of US male
ASSAF, respectively. The estimated cohort effect τ for the age groups 45-79 shows a clear
increasing-peaking-decreasing trend as observed in Figure 1. The estimated cohort effect τ˜
for the 80+ age group shows the same trend for the 13 cohorts reaching age 80 by 2015. We
could forecast any cohort effects based on the posterior distribution of the double logistic
function. The estimated age effect indicates that the smoking-attributed fraction of mortality
is higher among middle-aged males (aged 40–69) in the US than among older males (70 and
over). Figure 4 plots the posterior distributions of the means of the US male ASSAF for all
9 age groups and all 21 cohorts.
To project the future ASSAF, we first generate future cohort effects by plugging samples
drawn from the posterior distributions of country-specific parameters θ` and θ˜` in Eq. (2) and
(3). Then, we apply Eq. (1) using samples drawn from posterior distributions of the future
cohort effects, age effect, and country-specific variance σ2` to get projections of ASSAF.
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Figure 3: Posterior distributions of cohort and age effects of United States male ASSAF.
Top Left: posterior median and 95% credible intervals of the cohort effects τ for the 40–79
age groups. Bottom Left: posterior median and 95% credible intervals of the cohort effect τ˜
for the 80+ age groups. Right: boxplot of posterior distribution of the age effect.
2.4 Non-smoking Life Expectancy
The non-smoking life expectancy at birth, eNS0 , is the life expectancy at birth that a popula-
tion would have if no one smoked, but all mortality risks were otherwise the same (Bongaarts,
2006). To estimate eNS0 , we need the age-specific mortality rates dx and the ASSAF yx de-
scribed in Section 2.3. As in the last section, all quantities described in this section are
specific to the male population, and the sex index s is omitted unless otherwise specified.
The calculation of eNS0 consists of two steps. First, the age-specific non-smoking at-
tributable mortality rate for a given country `, age group x, and period t (denoted by dNS`,x,t)
is calculated as
dNS`,x,t := (1− y`x,t) · d`x,t. (4)
Second, we convert the set of dNS`,x,t to e
NS
0 using the standard period life table method
(Preston et al., 2000, Chapter 3), as implemented in the life.table function in the R package
MortCast (Sˇevcˇ´ıkova´ et al., 2019a). Figure 5 shows the relationship between quinquennial e0
and eNS0 for US males and Netherlands males from 1950 to 2015, respectively. The vertical
gap between e0 and e
NS
0 at each time point presents the years of life expectancy lost due to
smoking. The changes in the gaps also follow a similar increasing-peaking-decreasing trend
over the period 1950 to 2015.
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Figure 4: Posterior distributions of the means of US male ASSAF for all 9 age groups. The
observed ASSAF is shown by black dots. The posterior median and 95% credible intervals
of the means are shown by solid and dashed red lines, respectively.
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Figure 5: Male life expectancy at birth, e0, and male non-smoking life expectancy at birth,
eNS0 , for the United States (left) and the Netherlands (right). The black line shows e0. The
solid red line and the dashed red lines show the posterior median and the 95% credible
interval of eNS0 . The blue line represents the gap between e0 and e
NS
0 .
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2.4.1 Estimation and Forecasting: Non-linear Life Expectancy Gain Model
We forecast eNS0 by investigating the nonlinear five-year gains of e
NS
0 . As discussed by Raftery
et al. (2013), the improvement of gains on e0 for most of the countries has experienced a
slow-rapid-slow increasing pattern and a six-parameter double logistic function is used to
capture the non-linearity of five-year gains of e0:
g˜(e0|ζ) := w
1 + exp{−4.4
a2
(e0 − a1 − 0.5a2)} +
z − w
1 + exp{−4.4
a4
(e0 −
∑3
i=1 ai − 0.5a4)}
, (5)
where ζ := (a1, a2, a3, a4, w, z) and z is the asymptotic average rate of increase in e0. We
assume that z is nonnegative, implying that life expectancy will continue to increase on
average (Oeppen and Vaupel, 2002; Bongaarts, 2006).
The five-year gains in eNS0 exhibit this nonlinear pattern as well. The left panel of Figure
6 plots the observed five-year gains of e0 (in grey dots) and e
NS
0 (in red dots) for the 69
countries with data of high enough quality from 1950 to 2015. The five-year gains in eNS0
have nearly the same shape as the five-year gains in e0, which supports using the same double
logistic function to model the gains. Also, eNS0 has almost the same five-year gain at the
highest age as e0, suggesting that the asymptotic average rate of increase z for e
NS
0 should
be similar to that of e0. Further, the variability of the five-year gains of e
NS
0 changes from a
low level to a high level of eNS0 , which suggests including a nonconstant variance component
in the model.
We use a three-level Bayesian hierarchical model for eNS0 . Level 1 models e
NS
0,`,t for country
` and period t by
eNS0,`,t
ind∼ N (eNS0,`,t−1 + g˜(eNS0,`,t−1|ζ`), (ω` · φ(eNS0,`,t−1))2), (6)
with country-specific parameters ζ` := (a`1, a
`
2, a
`
3, a
`
4, w
`, z`). Here φ(·) is a regression spline
fitted to the absolute residuals resulting from the model with constant variance in Eq. (6)
with the same estimation method described later. The regression spline is used to account
for the changing variability of the observed data. The right panel of Figure 6 illustrates the
varying absolute residuals with the fitted spline in red. Level 2 specifies the conditional dis-
tribution for all country-specific parameters including ζ` and ω`. Level 3 sets the hyperpriors
for the global parameters ψ˜ := ({µai}4i=1, {σ2ai}4i=1, µw, σ2w, µz, σ2z). The full specification of
the model is given in the Appendix B.
To produce a probabilistic forecast, we sample from the joint posterior distributions of
the country-specific parameters ζ` to calculate the five-year gains g˜(eNS0 ) together with the
posterior distributions of ω`. For the variance component, we evaluate φ(eNS0,`,t−1) if e
NS
0,`,t−1 is
within the range of the fitted data; otherwise, it is set equal to the spline value evaluated at
the largest observed eNS0 . We then use Eq. (5) and (6) to generate samples from the posterior
predictive distribution for future country-specific eNS0,`,t. The set of samples approximates the
posterior predictive distribution.
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Figure 6: Left: Five-year gains of e0 and e
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0 for 69 countries from 1950 to 2015. The gains
in e0 and e
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0 are represented using grey and red dots, respectively. Right: Plot of absolute
residuals estimated from the constant variance model against life expectancy shown by black
dots, with fitted regression spline shown by the red line.
2.5 Male-Female Joint Forecast
2.5.1 Male e0 Forecast
First, we use the coherent Lee-Carter method (Li and Lee, 2005; Sˇevcˇ´ıkova´ et al., 2016) to
convert the projected eNS0,`,t back to d
NS
`,x,t for all age groups x at period t of country `. Then, we
invert Eq. (4) to get the projected age-specific all-cause mortality, i.e., d`x,t = d
NS
`,x,t/(1− y`x,t)
for any age groups x, period t, and country `. Finally, applying the same life table method
described in Section 2.4 to the forecast d`x,t, we obtain the forecast life expectancy at birth
for period t and country `. Figure 7 illustrates the projections of eNS0 and e0 for US and
the Netherlands males to 2060. The projected e0 converges to the projected e
NS
0 as ASSAF
decreases towards 0 for all age groups of US and the Netherlands males.
2.5.2 Female e0 Forecast: Gap Model
We propose a gap model similar to that of Raftery et al. (2014b) to produce a coherent pro-
jection of male-female life expectancy at birth. It has been argued that differences in smoking
largely account for the life expectancy gap between males and females (Preston and Wang,
2006; Wang and Preston, 2009). Here we explore the relationship between the between-sex
gap in life expectancy and the between-sex gap in the all-age smoking attributable fraction
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Figure 7: Projections of eNS0 and e0 of US (left) and the Netherlands (right) males to 2060.
The posterior medians and the 95% predictive intervals of projected eNS0 are shown by solid
and dashed red lines, respectively. The posterior medians and the 95% predictive intervals
of projected e0 are shown by solid and dashed black lines, respectively.
(ASAF). The ASAF is a single statistic summarizing the smoking effect on mortality and is
defined as a weighted average of the ASSAF values as calculated in Section 2.3, where the
weights are the age-specific mortality rates. Li and Raftery (2019) describe the estimation of
ASAF, as well as a method for forecasting it using a four-level Bayesian hierarchical model.
We modify the gap model of Raftery et al. (2014b) by adding the country-specific
between-sex ASAF gap as a covariate. The proposed gap model is as follows:
G`t := min{max{G˜`t, L}, U} (7)
G˜`t
ind∼ N (β0 + β1e`0,m,1953 + β2G`t−1 + β3e`0,m,t + β4(e`0,m,t −$)+ + β5h`t, σ2G),
where U and L are the observed historical maximum and minimum of the between-sex gap
in e0, $ is the level of male e0 at which the gap is expected to stop widening, and ht is the
between-sex gap (male minus female) of the posterior median of ASAF in period t.
The estimated parameters of the model based on the data for 69 countries for 1950–2015
are reported in Table 1. Our estimates indicate that the e0 sex gap has a strong positive
association with the ASAF gap after adjusting for other factors (βˆ5 = 1.180 with p-value
< 0.01). Since the estimated lower bound of the life expectancy gap L is positive, our model
guarantees that no crossover of male and female life expectancy forecasts will happen for all
trajectories. The other coefficients have similar estimates and significance as in Raftery et al.
(2014b), which accounts for the remaining variability in the between-sex life expectancy gap,
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Table 1: Estimated gap model coefficients with standard errors in parentheses, if available.
Variable Parameter Estimate Variable Parameter Estimate
Intercept β0 -2.173 (0.627) h
`
t β5 1.180 (0.384)
e`0,m,1953 β1 0.012 (0.003) σG 0.496
G`t−1 β2 0.901 (0.010) $ 61
e`0,m,t β3 0.043 (0.011) L 0.03
(e`0,m,t −$)+ β4 -0.107 (0.012) U 13.35
R2 0.933
possibly due to biological and other social factors (Janssen and van Poppel, 2015).
When performing projection, we forecast all terms in Eq. (7) forward. Instead of using
a random walk as in Raftery et al. (2014b), we make use of the ASAF gap to guide our
projection. However, we constrain the quantity (e`0,m,t −$)+ to be 20 when e`0,m,t is greater
than 81 years, which is the largest male e0 observed in countries of interest up to 2015,
since there is not enough information to determine whether the gap will continue to shrink
for higher e0. After the gender gap has been forecast, we add the gap to each posterior
trajectory of the forecast male e0 to get the full posterior predictive distribution of female
e0.
2.6 Estimation and Projection of the Full Model
We use data from 69 countries for which the data on the male smoking-attributable mor-
tality was of good enough quality. The precise data quality criteria and thresholds used are
described in Li and Raftery (2019). Of these 69 countries, two are in Africa, 16 are in the
Americas, nine are in Asia, 40 are in Europe and two in Oceania. Estimation of the full
model makes uses of male ASSAF, male age-specific mortality rates, both sexes e0, and both
sexes ASAF of all 69 clear-pattern countries over 13 five-year periods during 1950–2015.
Future e0 of the same set of countries over 9 five-year periods from 2015 to 2060 is projected
based on the joint posterior predictive distribution of the full model. The full procedure is
described in the Appendix A.
We use Markov Chain Monte Carlo (MCMC) to sample from the joint posterior distri-
butions of the parameters of interest. For the BHM of the ASSAF, we ran three chains, each
of length 100,000 iterations thinned by 20 iterations with a burn-in of 2,000. This yielded a
final, approximately independent sample of size 3,000 for each chain. For the BHM of each
of the 30 samples of eNS0 , we ran one chain with length 100,000 iterations thinned by 50 with
a burn-in of 1,000. This yielded a final, approximately independent sample of size 1,000 for
each chain. We monitored convergence by inspecting trace plots and using standard conver-
gence diagnostics, details of which are given in the Appendix B. We include the plots of e0
projections for all 69 countries and both sexes in the Appendix C.
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3 Results
We assess the predictive performance of our model using out-of-sample predictive validation.
3.1 Study design
The data we used for out-of-sample validation cover the period 1950–2015, dividing it into
an earlier training period and a later test period. We fit the model using only data from
the training period, and then generated probabilistic forecasts for the training period. We
finally compared the probabilistic forecasts with the observations for the training period.
We used two different choices of test period: 2000–2015, and 2010–2015. The former allows
us to assess longer-term forecasts, while the latter focuses on shorter-term forecasts.
To assess the accuracy of the probabilistic forecasts, we define the sex-specific mean
absolute error (MAE) as
MAEs =
1
|L||T |
∑
`∈L
∑
t∈T
|eˆ`0,s,t − e`0,s,t|, (8)
where L is the set of countries considered in the validation, T is the set of training periods,
and eˆ`0,s,t is the posterior median of the predictive distribution of life expectancy at birth
at year t for country ` and sex s. To assess the calibration and sharpness of the model,
we calculated the average empirical coverage of the prediction interval over the validation
period, which we hope to be close to its nominal level with as short a halfwidth of the interval
as possible (Gneiting and Raftery, 2007).
3.2 Out-of-sample validation
We evaluated and compared the performance of the proposed model with four commonly used
methods for forecasting e0: the Lee-Carter method (Lee and Carter, 1992), the Lee-Miller
method (Lee and Miller, 2001), the Hyndman-Ullah functional data method (Hyndman
and Ullah, 2007), and the Bayesian hierarchical model as implemented in the bayesLife R
package (Raftery et al., 2013). We refer to the last as the bayesLife method. The first three
methods were implemented using the corresponding functions with default settings in the
demography R package (Booth et al., 2006; Hyndman et al., 2019). The bayesLife method
was implemented under default settings using the R package bayesLife (Raftery et al., 2013,
2014b; Sˇevcˇ´ıkova´ et al., 2019b).
Table 2 gives the out-of-sample validation results for the four methods described above
as well as our proposed method. Our method had the smallest MAE for both sexes and both
choices of test period among the five methods. For predicting one five-year period ahead,
our method improved accuracy over the Lee-Carter method by 70% (60%), and over the
bayesLife method by 24% (11%) for males (females). For predicting three five-year periods
ahead, the new method improved accuracy over the Lee-Carter method by 53% (40%), and
over the bayesLife method by 24% (17%) for males (females).
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For model calibration, the Lee-Carter-type models produced predictive intervals that
are too narrow, thus underestimating the predictive uncertainty in the testing period. The
bayesLife method and the new method produced predictive intervals with coverage close to
the nominal level. We assess the sharpness of the forecast method using the 80% predic-
tive interval halfwidth. For male data under the three five-year periods prediction, the 80%
predictive interval of the new method was 30% shorter on average, but yielded the same
empirical coverage as the bayesLife method. Under the one five-year out-of-sample predic-
tions, the 80% predictive interval of the new method was 30% shorter on average but yielded
even higher empirical coverage than the bayesLife method. For female data, the predictive
intervals of our method overcovered the observations slightly for each choice of test period,
but their median halfwidths were not much wider than those of the bayesLife method (e.g.,
the largest increment was less than 18%). The major source of variability in the female
projections of the new method comes from the gap model.
Table 2: Out-of-sample validation results for forecasting life expectancy at birth of males
and females one and three five-year periods ahead. “Num” is the number of countries used
in the validation. In the “Method” column, “H-U FDA” is the Hyndman-Ullah functional
data analysis method, “bayesLife” represents the method described in Raftery et al. (2013),
and “smokeLife” is the our proposed method. “Halfwidth” represents the median of the
halfwidth of the prediction interval.
Period Num Sex Method MAE
Coverage Halfwidth
80% 95% 80% 95%
Train:1950–2000
67
M
Lee-Carter 2.043 0.144 0.199 0.368 0.568
Lee-Miller 1.536 0.318 0.418 0.831 1.239
H-U FDA 2.206 0.189 0.274 0.808 1.259
bayesLife 1.273 0.741 0.950 1.722 2.714
smokeLife 0.962 0.741 0.896 1.197 1.943
Test: 2000–2015 F
Lee-Carter 1.210 0.199 0.294 0.391 0.599
Lee-Miller 0.748 0.602 0.756 0.612 0.940
H-U FDA 1.430 0.114 0.299 0.412 0.633
bayesLife 0.876 0.816 0.955 1.312 1.985
smokeLife 0.718 0.891 1.000 1.380 2.173
Train:1950–2010
68
M
Lee-Carter 1.741 0.103 0.118 0.306 0.448
Lee-Miller 0.853 0.544 0.721 0.581 0.931
H-U FDA 1.364 0.191 0.324 0.548 0.791
bayesLife 0.688 0.824 0.897 1.098 1.748
smokeLife 0.523 0.912 0.985 0.773 1.250
Test: 2010–2015 F
Lee-Carter 1.025 0.118 0.221 0.279 0.436
Lee-Miller 0.486 0.662 0.779 0.476 0.708
H-U FDA 0.895 0.250 0.368 0.373 0.573
bayesLife 0.464 0.868 0.941 0.853 1.291
smokeLife 0.413 0.971 1.000 0.974 1.517
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4 Case studies
On average, smoking results in 1.4 years lost of male life expectancy at birth for the 69
countries over 1950-2015. The trend in years lost due to smoking also follows the pattern of
the smoking epidemic. The average years lost due to smoking among males increased from
0.9 in 1953 to a maximum of 1.7 in 1993, and decreased to 1.3 in 2013.
For male populations of most countries, the ASSAF has already passed the peak for most
age groups. When this is the case, accounting for the smoking effect leads to higher forecasts
of life expectancy at birth. On average, our proposed method gives forecasts of male life
expectancy at birth that are 1.1 years higher than the bayesLife method used by the UN for
the 69 countries over the period 2015–2060.
Most female populations are still at the increasing or peaking stage of the smoking epi-
demic. However, for 2055-2060, we expect to see an increment of 1.0 in female life expectancy
compared to the forecast result from the bayesLife method, since the female smoking epi-
demic will be following the same decreasing trend as that of males by then.
We now study four countries in detail, representing different patterns of the smoking
epidemic.
4.1 United States
The United States of America has one of the best vital registration systems in the world
and also high quality data on cause of death. It thus has high quality data on the SAF.
The smoking epidemic started in the early 1900s among the male population and rose to the
historical maximum of around 60% in the 1950s. At that point, government programs and
social movements against smoking began to develop, and the US public became increasingly
aware of the adverse impacts of smoking. Since then, there has been a substantial decrease
in smoking prevalence, going down to about 20% in the 1990s, and 17.5% in 2016 (Burns
et al., 1997; Islami et al., 2015).
The female smoking epidemic started two decades later than the male one with a max-
imum prevalence of around 30% in the 1960s. Female smoking prevalence decline to about
20% in 1990s and 13.5% in 2016 (Burns et al., 1997; Islami et al., 2015). Figure 8a shows
projections of the US male and female ASAF to 2060. Figure 8b predicts a continuously
narrowing gap of the between-sex life expectancy due to the shrinking gap between male and
female ASAF up to 2060.
Figures 8c and 8d show projections of male and female life expectancy for the period
2015-2060. The bayesLife method projects male life expectancy in 2055-2060 to be 84.0
years, with 95% predictive interval (79.2, 87.6). We project male life expectancy to be 86.1
in 2060, with 95% predictive interval (83.0, 88.9). The bayesLife method projects US female
life expectancy for 2055-2060 to be 86.5 with 95% predictive interval (82.9, 90.0). We project
female life expectancy to be 88.6 with interval (84.8, 92.4).
Our method gives forecasts of life expectancy that are about two years higher than
those from the bayesLife method for both males and females, because of accounting for the
smoking effect. Our predictive interval for male life expectancy at birth is 29% shorter than
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the bayesLife one, while our female interval is comparable with that of the bayesLife method.
Both of our 95% predictive intervals cover the posterior medians from the bayesLife method.
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Figure 8: United States of America. (a) All-age smoking attributable fraction (ASAF) for
male (black) and female (red) with median and 95% PI of posterior predictive distributions.
(b) Between-sex gap of life expectancy at birth with posterior predictive median (red solid)
and 95% PI (red dotted). (c) Forecasts of male life expectancy at birth to 2060 using
bayesLife method (green) and our proposed method (red) with posterior predictive medians
(dashed) and 95% PI (dotted). (d) Forecasts of female life expectancy at birth to 2060 using
bayesLife method (green) and our proposed method (red) with posterior predictive medians
(dashed) and 95% PI (dotted).
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4.2 The Netherlands
The Netherlands is a western European country with a long history of the smoking epidemic,
which can be dated back to the 1880s when the cigarette industry began there. Male smoking
prevalence reached 90% in most age groups in the 1950s, but dropped rapidly to 30% in the
2010s. In contrast, smoking was more prevalent among females in the 1970s, when about
40% of female smoked, and after 1975 there was a sustained drop to 24% in the 2010s
(Stoeldraijer et al., 2015).
Figure 9a shows that the female ASAF is forecast to surpass the male ASAF for the
next two decades and by 2060, both male and female ASAF will be at about the same level.
Figure 9b shows that the turning point in the between-sex gap of life expectancy happened
around the 1990s, when the male ASAF had passed its peak and the female ASAF started
to climb. With the shrinking of the ASAF gap, the projected life expectancy gap is forecast
to continue to shrink and plateau around 2.8, due to biological and social factors (Janssen
and van Poppel, 2015).
Both Dutch males and females experienced a period of stagnation in life expectancy
gains—in the 1960s for males and the 1990s for females. Smoking is a major reason for
this stagnation. The right panel of Figure 5 indicates that the forecast Dutch male life
expectancy gain is more linear and sustained after removing the smoking effect. Figures 9c
and 9d show projections of male and female life expectancy for 2015–2060. We project male
life expectancy for the period 2055-2060 to be 88.0 years, with a 95% prediction interval
of (85.0, 91.1), while the bayesLife method projects 86.1, with interval of (82.3, 89.7). We
project female life expectancy for the period 2055-2060 to be 90.8, with a 95% prediction
interval of (86.6, 95.0), while the bayesLife method projects 88.4 years, with interval of (85.1,
91.9).
Similarly to the US, our forecast of life expectancy in 2060 is about two years higher
than a forecast that does not take account of smoking. By considering the decreasing trend
of the smoking epidemic, our forecast is 1.9 years higher for males and 2.3 years higher for
females expectancy compared with the bayesLife method. Janssen et al. (2013) forecast the
Dutch male and female life expectancy in 2040 to be 84.6 years and 87.2 years respectively,
taking account of smoking. This agrees well with our forecasts —85.0 for males and 87.3 for
female—in 2040.
4.3 Chile
Chile is a South American country where the smoking epidemic had a late start, and it is
currently one of the countries with the highest smoking prevalence in the Americas. Smoking
prevalence decreased from 50% in 2000 to 40% in 2016 among males, and from 44% to 36%
among females. This decline is modest compared to that in the United States (Islami et al.,
2015).
Figure 10a shows the projections of male and female ASAF. Chilean male ASAF has
been at the peaking stage for a long time, with high prevalence and no sign of a decline.
Female ASAF is predicted to grow to approach the male level. The narrowing of the ASAF
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Figure 9: The Netherlands. (a) All-age smoking attributable fraction (ASAF) for male
(black) and female (red) with median and 95% PI of posterior predictive distributions. (b)
Between-sex gap of life expectancy at birth with posterior predictive median (red solid) and
95% PI (red dotted). (c) Forecasts of male life expectancy at birth to 2060 using bayesLife
method (green) and our proposed method (red) with posterior predictive medians (dashed)
and 95% PI (dotted). (d) Forecasts of female life expectancy at birth to 2060 using bayesLife
method (green) and our proposed method (red) with posterior predictive medians (dashed)
and 95% PI (dotted).
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gap is forecast to lead to a sustained closing of the life expectancy between-sex gap (Figure
10b).
Figures 10c and 10d show projections of male and female life expectancy for 2015–2060.
We project male life expectancy for the period 2055-2060 be 83.2, with a 95% predictive
interval of (80.9, 86.3). In contrast with the USA and the Netherlands, our median projection
is 1.8 years less than that from bayesLife method. This is due to the fact that the epidemic
has not yet clearly peaked. We project female life expectancy to be 84.5, with a 95%
predictive interval of (81.7, 88.5), which is again substantially smaller than that from the
bayesLife method with forecast median 87.6 years and 95% prediction interval (84.1, 91.0).
This is due to the increasing impact of smoking on the Chilean female population.
4.4 Japan
Japan has been a leading country in life expectancy for a long period, while it also has a long
history of smoking and is one of the largest tobacco consumers. Male smoking prevalence
reached 83.7% in 1966. That number dropped to 36% in the 1990s and halved again by 2018.
Female smoking prevalence is far lower and changes less dramatically than that of males.
Female smoking prevalence reached 16% in the 1970s and decreased to 9.7% in 2015. The
significant changes result mainly from government regulations and anti-smoking movements
starting in the 1980s. Figure 11a shows the forecast male and female ASAF. Figure 11b
shows the narrowing of the life expectancy gap as a result.
Figures 11c and 11d show projections of life expectancy for males and females. We project
male life expectancy for the period 2055-2060 to be 88.8, with a 95% predictive interval of
(85.8, 91.5). The bayesLife method forecasts 85.6, with a projection interval (81.6, 89.7).
Notice that our median forecast is 3.2 years higher than that of bayesLife, while its interval
is 1.4 years narrower. We project female life expectancy to be 92.2 with a 95% prediction
interval of (88.3, 96.1). Our forecast shows a noticeable slowdown of the growth of female
life expectancy due to the smoking effect. The bayesLife method projects 92.0 years with
interval (88.8, 95.3). Though both methods produce comparable forecast results for 2055-
2060, the bayesLife method forecasts a more linear increase while ours reflects the nonlinear
smoking effect on the life expectancy forecast.
5 Discussion
We have proposed a method for probabilistic forecasting of mortality and life expectancy that
takes account of the smoking epidemic. The method is based on the idea of the smoking
attributable fraction of mortality, as estimated by the Peto-Lopez method using data on
lung cancer mortality. The age-specific smoking attiributable fraction (ASSAF) of mortality
is estimated and used to infer the non-smoking life expectancy at birth, eNS0 . Both the
ASSAF and eNS0 are then forecast using a Bayesian hierarchical models for all countries with
sufficiently good data. This in turn yields posterior predictive distributions of mortality rates
19
l l
l
l
l
l
l l
l l l l
l
1960 1980 2000 2020 2040 2060
0.
00
0.
05
0.
10
0.
15
Year
AS
AF
l l l l l l l l l
l
l
l
l
l
l
male obs
male med
male 95% PI
female obs
female med
female 95% PI
(a)
l
l
l
l
l
l l
l
l l l
l
l
1960 1980 2000 2020 2040 2060
0
1
2
3
4
5
6
Year
e
0 
G
ap
l obs
proj med
proj 95%PI
(b)
l
l
l
l
l
l
l
l
l
l
l
l
l
1960 1980 2000 2020 2040 2060
60
70
80
90
Year
e
0
l obs
smokeLife med
smokeLife 95%
bayesLife med
bayesLife 95%
(c)
l
l
l
l
l
l
l
l
l
l
l l
l
1960 1980 2000 2020 2040 2060
60
70
80
90
Year
e
0
l obs
smokeLife med
smokeLife 95%
bayesLife med
bayesLife 95%
(d)
Figure 10: Chile. (a) All-age smoking attributable fraction (ASAF) for male (black) and
female (red) with median and 95% PI of posterior predictive distributions. (b) Between-
sex gap of life expectancy at birth with posterior predictive median (red solid) and 95% PI
(red dotted). (c) Forecasts of male life expectancy at birth to 2060 using bayesLife method
(green) and our proposed method (red) with posterior predictive medians (dashed) and 95%
PI (dotted). (d) Forecasts of female life expectancy at birth to 2060 using bayesLife method
(green) and our proposed method (red) with posterior predictive medians (dashed) and 95%
PI (dotted).
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Figure 11: Japan. (a) All-age smoking attributable fraction (ASAF) for male (black) and
female (red) with median and 95% PI of posterior predictive distributions. (b) Between-
sex gap of life expectancy at birth with posterior predictive median (red solid) and 95% PI
(red dotted). (c) Forecasts of male life expectancy at birth to 2060 using bayesLife method
(green) and our proposed method (red) with posterior predictive medians (dashed) and 95%
PI (dotted). (d) Forecasts of female life expectancy at birth to 2060 using bayesLife method
(green) and our proposed method (red) with posterior predictive medians (dashed) and 95%
PI (dotted).
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and life expectancy at birth. The method performed well in an out-of-sample validation
study.
The strength of the method derives from the fact that the smoking attributable fraction of
mortality follows a very strong increasing-peaking-decreasing trend over time in all countries
where the smoking epidemic has been going for long enough. This pattern is strong, broadly
the same across countries, is to a large extent socially determined, and is also not highly
correlated over time with the life expectancy at birth itself, which follows a broadly increasing
pattern over time. However, smoking does impact mortality. Thus smoking mortality can be
predicted with considerable accuracy, and accurate predictions improve mortality forecasts.
Another strength of the method is its use of a hierarchical model, which greatly facili-
tates forecasting, particularly for countries where the smoking epidemic is at an early stage.
This allows forecasts for such countries to be informed by information from other countries,
especially those where the epidemic is more advanced. It also makes it easier to incorporate
all major sources of uncertainty.
The results indicate that for country-sex combinations where the smoking epidemic is
advanced enough that we can expect it to be declining by 2060, incorporating smoking
increases forecasts of life expectancy by about two years. When the epidemic is at an earlier
stage, though, incorporating smoking tends to reduce forecasts of life expectancy. The results
also indicate that much of change over time in the female-male gap in life expectancy is due
to relative changes in smoking related mortality.
The biggest limitation of our method is that it relies on the availability of high-quality
data on cause of death, particularly lung cancer, which are available for only 69 countries of
the 201 or so countries in the world. Thus the biggest improvement in the method would
come from improvements in data quality. In particular, China and India are missing from
our study, because national data on cause of death of high enough quality are not available.
Producing such data should be a focus of future data collection and research. This is very
important because, not only are China and India the two most populous countries in the
world, but they also have high smoking rates and are likely to experience high smoking
mortality in the coming decades.
Several other approaches to the problem have been proposed. Bongaarts (2006) intro-
duced the concept of non-smoking life expectancy, and proposed modeling it in a linear
way. However, the time evolution of non-smoking life expectancy appears generally to follow
a nonlinear pattern, with gains that broadly follow a non-monotonic increasing-peaking-
declining patter. This is modeled in our method by a random walk with a the double logistic
drift.
Janssen et al. (2013) proposed directly modeling the ASSAF and the age-specific non-
smoking attributable mortality rates. They observed that non-smoking mortality rates de-
cline more linearly than overall mortality rates, making the data fit a Lee-Carter model
better. They conducted an age-period-cohort analysis, while we found an age-cohort model
to be sufficient. There are well-known identifiability issues with age-period-cohort analysis
that our approach avoids. They used a coherent Lee-Carter method. This assumes linear
progress in log mortality rates, while in fact progress tends to be nonlinear, and also tends to
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be more linear on the scale of life expectancy than of log mortality rates, which our double
logistic random walk attempts to represent.
The mortality component of the UN’s population projections for all countries is based
on the Bayesian hierarchical model of Raftery et al. (2013), which does not take account
of smoking. We have shown that this could be improved significantly by taking account of
smoking. However, the data to do this are available for only 69 countries currently, and
the UN aims to use a unified approach for all the 230 countries and territories that they
analyze. Thus extending the UN’s method to take account of smoking in this way might
not be feasible in the short term. To do this would likely require a major improvement in
data availability for many countries. However, it could be useful for national population and
mortality projections for individual countries, for example for planning health services, and
also for the private sector, for example for actuarial and insurance analyses.
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Appendices
A Full Bayesian Hierarchical Model
We first describe the estimating and projection of the full model.
1. Estimate and forecast the male ASSAF using the 3-level Bayesian hierarchical model
described in Section 2.3, and generate 30 samples from the posterior distributions of
the mean of ASSAF of all 69 clear-pattern countries for all 13 five-year estimation
periods and all 9 five-year periods forecast period;
2. For each country, generate 30 samples of male eNS0 based on the ASSAF samples
drawn in Step 2 for all 13 five-year estimation periods, and for each of the 30 samples,
forecast male eNS0 of all 69 countries for all 9 five-year periods using the 3-level Bayesian
hierarchical model described in Section 2.4;
3. For each country, forecast male e0 based on the method described in Section 2.5.1 for
each of the 30 samples, and combine trajectories from all 30 samples to get the full
posterior predictive distribution of male e0;
4. For each country, apply the gap model described in Section 2.5.2 to the combined
trajectories of male e0 to get the full posterior predictive distribution of female e0.
The Bayesian hierarchical model for modeling age-specific smoking attributable fraction
(ASSAF) described in Section 2.3 is specified as follows.
Level 1: y`x,t
ind∼ N (ξ`xτ `t−x1x 6=80 + ξ`xτ˜ `t−x1x=80, σ2` );
Level 2: β`40 = 1, β
`
x|µ[β]x , σ2[β]x i.i.d∼ N (µ[β]x , σ2[β]x ) for all x except 40,
τ `c |θ`, σ2[τ ] ind∼ N (g(c|θ`), σ2[τ ]), τ˜ `c |θ˜`, σ2[τ ] ind∼ N (g(c|θ˜`), σ2[τ ]) for c = t− x,
4`1|µ41 i.i.d∼ G(2, 2/µ41), 4`2|µ42 , σ242
i.i.d∼ N (µ42 , σ242),
4`3|µ43 i.i.d∼ G(2, 2/µ43), 4`4|µ44 , σ244
i.i.d∼ N (µ44 , σ244),
k`|µk, σ2k i.i.d∼ N (µk, σ2k), δ`|µδ, σ2δ i.i.d∼ N (µδ, σ2δ ),
σ2` |σ2 i.i.d∼ IG(2, σ2);
Level 3: µ[β]x
i.i.d∼ N (1, 5), σ2[β]x i.i.d∼ IG(2, 5),
σ2 ∼ IG(2, 0.01), σ2[τ ] ∼ IG(2, 0.01),
µ41 ∼ G(2, 0.1), µ42 ∼ N (20, 1000),
µ43 ∼ G(2, 0.1), µ44 ∼ N (20, 1000),
µk ∼ N (0.3, 0.25), µδ ∼ N (0, 100),
σ242 ∼ IG(2, 1000), σ244 ∼ IG(2, 1000),
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σ2k ∼ IG(2, 0.25), σ2δ ∼ IG(2, 100),
where θ` := (4`1,4`2,4`3,4`4, k`), θ˜` := (4`1,4`2,4`3,4`4 + δ`, k`), and
g(c|θ) = k
1 + exp{−41(c− 1873−42)} −
k
1 + exp{−43(c− 1873−42 −44)} .
The Bayesian hierarchical model for modeling non-smoking life expectancy (eNS0 ) de-
scribed in Section 2.4 is specified as follows.
Level 1: eNS0,`,t
ind∼ N (eNS0,`,t−1 + g˜(eNS0,`,t−1|ζ`), (ω` · φ(eNS0,`,t−1))2);
Level 2: a`i |µai , σ2ai
i.i.d∼ N[0,100](µai , σ2ai), i = 1, · · · , 4,
w`|µw, σ2w i.i.d∼ N[0,15](µw, σ2w), z`|µz, σ2z i.i.d∼ N[0,1.15](µz, σ2z),
ω`
i.i.d∼ U[0,10];
Level 3: µa1 ∼ N (15.77, 15.62), µa2 ∼ N (40.97, 23.52),
µa3 ∼ N (0.21, 14.52), µa4 ∼ N (19.82, 14.72),
µw ∼ N (2.93, 3.52), µz ∼ N (0.40, 0.62),
σ2a1 ∼ IG(2, 15.62), σ2a2 ∼ IG(2, 14.52),
σ2a3 ∼ IG(2, 14.72), σ2a4 ∼ IG(2, 3.52),
σ2w ∼ IG(2, 0.62), σ2z ∼ IG(2, 0.62),
where ζ := (a1, a2, a3, a4, w, z) and
g˜(eNS0 |ζ) :=
w
1 + exp{−4.4
a2
(eNS0 − a1 − 0.5a2)}
+
z − w
1 + exp{−4.4
a4
(eNS0 −
∑3
i=1 ai − 0.5a4)}
.
B MCMC Diagnostics
We check the convergence of BHM for ASSAF based on trace plots and diagnostics (Raftery
and Lewis, 1992) for the global parameters in Level 3. We check one chain with 2,000 burn
in iterations and 100,000 samples, with a thinning period of 20 iterations. Table 3 shows the
summary statistics of the diagnostics. Figure 12 shows the trace plots of all 3,000 samples
of the global parameters.
We do the same for eNS0 . We check one of the 30 samples with 1,000 burn in iterations,
100,000 samples and a thinning period of 50 iterations. Table 4 shows the summarizing
statistics of the diagnostics. Figure 13 shows the trace plots of all 1,000 samples of the
global parameters.
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Table 3: Diagnostic statistics for global parameters in BHM for ASSAF. Burn1, Size1, and
DF1 are the length of burn-in, required sample size, and dependence factor of the Raftery-
Lewis diagnostics with parameters q = 0.025, r = 0.0125, and s = 0.95. Burn2, Size2, and
DF2 are the same, but for q = 0.975.
Parameters Burn1 Size1 DF1 Burn2 Size2 DF2
µ
2[β]
40 - - - - - -
µ
2[β]
45 2 606 1.01 2 631 1.05
µ
2[β]
50 2 641 1.07 2 581 0.97
µ
2[β]
55 2 577 0.96 2 631 1.05
µ
2[β]
60 2 616 1.03 2 591 0.98
µ
2[β]
65 2 601 1.00 2 621 1.03
µ
2[β]
70 2 616 1.03 2 621 1.03
µ
2[β]
75 2 587 0.98 2 611 1.02
µ
2[β]
80 2 626 1.04 3 664 1.11
σ
2[β]
40 - - - - - -
σ
2[β]
45 3 669 1.12 3 653 1.09
σ
2[β]
50 2 601 1.00 2 601 1.00
σ
2[β]
55 2 591 0.98 2 621 1.03
σ
2[β]
60 2 606 1.01 2 572 0.95
σ
2[β]
65 2 611 1.02 2 611 1.02
σ
2[β]
70 1 595 0.99 2 591 0.98
σ
2[β]
75 3 648 1.08 2 641 1.07
σ
2[β]
80 2 621 1.03 3 676 1.13
σ 2 591 0.98 3 658 1.10
σ2[τ ] 2 591 0.98 3 648 1.08
µ41 6 1308 2.18 9 2040 3.40
µ42 8 1610 2.68 2 641 1.07
σ242 12 2160 3.60 8 1586 2.64
µ43 4 790 1.32 3 686 1.14
µ44 12 1980 3.30 15 2211 3.68
σ244 6 1701 2.84 8 1656 2.76
µk 6 1432 2.39 8 1456 2.43
σ2k 4 1236 2.06 4 771 1.28
µδ 18 3090 5.15 24 4912 8.19
σ2δ 15 2499 4.16 30 6955 11.60
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Figure 12: Traceplots for the hyperparameters in BHM for ASSAF.
30
Table 4: Diagnostic statistics for global parameters in BHM for eNS0 . The quantities shown
are defined as in Table 3.
Parameters Burn1 Size1 DF1 Burn2 Size2 DF2
µa1 164 14734 24.60 3 703 1.17
σ2a1 2 596 0.99 3 648 1.08
µa2 2 572 0.95 81 10795 18.00
σ2a2 3 648 1.08 3 648 1.08
µa3 2 572 0.95 7 1179 1.96
σ2a3 2 596 0.99 2 621 1.03
µa4 3 703 1.17 6 1005 1.68
σ2a4 3 675 1.12 5 867 1.44
µw 3 648 1.08 2 596 0.99
σ2w 2 572 0.95 2 596 0.99
µz 3 662 1.10 2 572 0.95
σ2z 2 596 0.99 3 689 1.15
Figure 13: Traceplots for the hyperparameters in BHM for eNS0 .
31
C Life Expectancy Forecast Plots of 69 Countries
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